Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: A PCCTC trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Neoplasm Proteins
  • Prostatic Neoplasms

abstract

  • AGS-1C4D4 was well-tolerated and demonstrated linear PK. Despite preclinical differences in antibody-dependent cellular cytotoxicity, AGS-1C4D4 and AGS-PSCA have similar safety and PK profiles. The recommended Phase II dose is 48 mg/kg.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3586214

Digital Object Identifier (DOI)

  • 10.1007/s00280-011-1759-9

PubMed ID

  • 22020316

Additional Document Info

start page

  • 763

end page

  • 71

volume

  • 69

number

  • 3